A long-acting synthetic form of the hormone IGF-1. No studies with random groups. The approved IGF-1 medicine (Increlex) is a different product. Muscle mass: grade E, not clear. There are no studies in people. Given for a week to unborn lambs with slowed growth, it did not raise their weight. Muscle was not measured.

PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). US: No approval. The FDA drug register has no such medicine.

Short entry. It has study grades and sources. We are still writing the full description.

IGF-1 LR3

Long R3 IGF-1

A long-acting synthetic form of the hormone IGF-1. No studies with random groups. The approved IGF-1 medicine (Increlex) is a different product.

This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.

Type: Hormone
Stage: Lab and animals only
Safety: Not known
Doping: Banned in sport, WADA 2026
Risk of fakes: High
Checked: Not yet

Safety. We found no safety study in people. A 2019 review links growth hormone and IGF-1 to the ways cancers develop. Sources: study 1.

Risk of fakes. A lab in Cologne found an unpurified version of this substance in seized products. Sources: study 1.

Is it legal

Where	Status		Checked
PL	No approval	The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source	Not yet
EU	No approval	The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source	Not yet
US	No approval	The FDA drug register has no such medicine. Source	Not yet

How much research exists

Scientific papers: 99
Studies with random groups: 0
Registered studies in people: 0

These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.

What studies show

EMuscle mass
Not clear. There are no studies in people. Given for a week to unborn lambs with slowed growth, it did not raise their weight. Muscle was not measured.

Reported side effects

What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.

Reports to the FDA (USA)

Reports: 0
Of these, serious: 0

The FDA has no reports. That is not a sign of safety: almost nobody reports substances from outside pharmacies.

Cases described in medical journals

We found no published case of harm.

FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.

Studies we have read

Studies	Kind of study	Who was studied	People	Duration	Dose as studied	Who paid
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.Am J Physiol Endocrinol Metab 2025	In animals	sheep, Growth-restricted fetal sheep	14	1 wk	–	Unknown

More papers we found

Studies	Kind of study	Year
Insulin-like growth factor I receptor expression and function in fibroblasts from two patients with deletion of the distal long arm of chromosome 15.J Clin Endocrinol Metab	Case reports	1995
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Front Endocrinol (Lausanne)	Review of studies	2026
The role of insulin-like growth factors in small intestinal cell growth and development.Horm Metab Res	Review of studies	1999
Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.Int J Biol Macromol	In animals	2025
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.J Dev Orig Health Dis	In animals	2023
N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling.Int J Mol Sci	In animals	2022
Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect.Am J Physiol Endocrinol Metab	In animals	2021
IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus.Am J Physiol Endocrinol Metab	In animals	2021

We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.

All papers and studies we found (91)

Short answers

Does IGF-1 LR3 work?: A long-acting synthetic form of the hormone IGF-1. No studies with random groups. The approved IGF-1 medicine (Increlex) is a different product. Muscle mass: grade E, not clear. There are no studies in people. Given for a week to unborn lambs with slowed growth, it did not raise their weight. Muscle was not measured.
Is IGF-1 LR3 legal?: PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). US: No approval. The FDA drug register has no such medicine.
Is IGF-1 LR3 banned in sport?: Banned in sport, WADA 2026.
Is IGF-1 LR3 safe?: Not known. We found no safety study in people. A 2019 review links growth hormone and IGF-1 to the ways cancers develop.

Plain text for machines